Cite
HARVARD Citation
Sands, B. et al. (n.d.). OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. Journal of Crohn's and colitis. pp. i042-i043. [Online].